Plasma Amyloid-β (Aβ 42 ) Correlates with Cerebrospinal Fluid Aβ 42 in Alzheimer’s Disease

Abstract

The 42 amino acid form of amyloid-β (Aβ₄₂) plays a key role in the pathogenesis of Alzheimer’s disease (AD) and is a core biomarker for the diagnosis of AD. Numerous studies have shown that cerebrospinal fluid (CSF) Aβ₄₂ concentrations are decreased in AD, when measured by enzyme-linked immunosorbent assay (ELISA) and other conventional immunoassays. While most studies report no change in plasma Aβ₄₂, independent studies using the immunomagnetic reduction (IMR) technique report an increase in plasma Aβ₄₂ levels in AD. To confirm the opposite changes of Aβ₄₂ levels in CSF and plasma for AD, we assayed the levels of Aβ₄₂ in plasma of subjects with known CSF Aβ₄₂ levels. In total 43 controls and 63 AD patients were selected at two sites: the VU University Medical Center (n = 55) and Sahlgrenska University Hospital (n = 51). IMR and ELISA were applied to assay Aβ₄₂ in plasma and CSF, respectively. We found a moderately negative correlation between plasma and CSF Aβ₄₂ levels in AD patients (r = –0.352), and a weakly positive correlation in controls (r = 0.186). These findings further corroborate that there are opposite changes of Aβ₄₂ levels in CSF and plasma in AD. The possible causes for the negative correlation are discussed by taken assay technologies, Aβ₄₂ transport from brain to peripheral blood, and sample matrix into account.

Keywords

Amyloid-β cerebrospinal fluid immunomagnetic reduction plasma

INTRODUCTION

There is a strong demand for fluid-based biomarkers for Alzheimer’s disease (AD) in both the research and clinical context, with applications in clinical diagnosis, developing AD-related drugs, and as screening tools in clinical trials, for example in the pre-screen of patients for amyloid positron emission tomography (PET) [1 –8]. Quantifications of cerebrospinal fluid (CSF) biomarkers such as Aβ₄₂, total tau (t-Tau), and phosphorylated tau (p-Tau) proteins have been incorporated into standard diagnostic guidelines for AD [1, 2]. It has been demonstrated that the change in CSF Aβ₄₂ level happens 10–20 years earlier than the onset of clinical symptoms [3, 4]. The CSF Aβ₄₂ level was found to be significantly reduced in individuals with AD [5 –9]. For inclusion of Aβ₄₂ analysis as the first step in a multiple process to screen preclinical AD, it is important to be able to measure it with a low cost and non-invasive method, such as blood analysis. However, the AD-related biomarkers in blood are very low abundant and thus ultra-sensitive assay technologies are needed to measure AD-related biomarkers in blood samples. This demand motivated several groups to develop ultra-sensitive assays. Several technologies for peripheral blood analysis have been developed, such as single-molecule array (Simoa), single-molecule counting (SMC), multi-analyte profiling (xMAP), and mass spectrometry (MS)-based quantification [10 –15]. So far, the results have been inconsistent showing increased, unchanged or decreased plasma Aβ₄₂ concentrations in AD and no overall significant change upon meta-analysis [16]. The low levels of Aβ₄₂ in blood together with its short half life and matrix effects pose strong requirements on the methodologies [17].

An ultra-sensitive immunoassay with high sensitivity and low interference called immunomagnetic reduction (IMR) assay was developed to quantify blood Aβ₄₂ level [18, 19]. According to the results in a Taiwanese cohort, blood Aβ₄₂ level measured using IMR is approximately 15 pg/ml in healthy elderly individuals [20]. Interestingly, blood Aβ₄₂ levels are increased in early AD (specifically mild cognitive impairment (MCI) due to AD and mild AD in the two studies) [20, 21]. Importantly, higher blood Aβ₄₂ level in AD patients than healthy control was also observed in a study based on a US patient cohort [22]. The good consistency between the studies in Taiwan and US shows the high reliability and promising utilities of blood-based biomarkers for both research and clinical uses of AD using the IMR assay.

According to the published reports by independent groups, significant changes in Aβ₄₂ level in both CSF and in plasma in AD were found, but with an opposite change in Aβ₄₂ between CSF (reduced levels) and plasma (higher levels), which implies that there is an inverse correlation for Aβ₄₂ between CSF and plasma. However, the cohorts in the CSF studies were different from the above studies, precluding the possibility to directly correlate Aβ₄₂ levels between CSF and plasma in the same cohort. Therefore, in the present study, the levels of plasma Aβ₄₂ (measured with IMR) were directly compared and correlated with those in CSF (measured with ELISA) in the same cohort, that included 106 samples from 63 AD patients and 43 controls from two independent sites. In addition to examining the correlation in Aβ₄₂ level between CSF and plasma, possible factors contributing to the correlation are discussed.

MATERIALS AND METHODS

Study populations

Two sites enrolled subjects and analyzed CSF Aβ₄₂. The first site was the Clinical Neurochemistry Laboratory, Sahlgrenska University, Mölndal, Sweden (GOT), and the samples consisted of de-identified CSF samples from clinical diagnostic routine, following procedures approved by the Ethical Committee at University of Gothenburg. The AD group included patients with cognitive deterioration who had pathological CSF AD core biomarker levels using optimized cut-off levels for AD, specifically Aβ_1 - 42 <530 pg/ml, t-tau >350 pg/ml, and p-tau >60 pg/ml [23]. The control group included patients with minor psychiatric or neurological complaints, but with normal basic CSF tests (cell count, CSF/serum albumin ratio, IgG and IgM index), thereby excluding disorders affecting the blood-brain barrier function, including inflammatory CNS disorders [10], together with normal levels of the core AD biomarkers.

The second site was the Alzheimer Center at VU University Medical Center (AMST). We selected 53 patients (n = 34 AD patients and n = 19 controls) from the Amsterdam Dementia Cohort [24]. All patients underwent standard dementia screening at baseline, including physical and neurological examination, electroencephalogram (EEG), magnetic resonance imaging (MRI), and laboratory tests. Cognitive screening included at least a Mini-Mental State Examination (MMSE). Diagnoses were made by consensus in a multidisciplinary team without knowledge of CSF results. Controls were individuals with subjective cognitive decline (SCD), i.e., all clinical examinations and test results for MCI or AD were negative, and there was no psychiatric diagnosis, similar as the GOT control group. All probable AD patients met the core clinical NIA-AA criteria [1]. All subjects gave written informed consent for the use of clinical data for research purposes and the use of clinical data was approved by the local ethical review board.

CSF biochemical analysis

CSF sampling and analyses followed similar protocols for both sites. In short, CSF was obtained by lumbar puncture, using a 25-gauge needle, and collected in 10 ml polypropylene tubes (Sarstedt, Nümbrecht, Germany). Within 2 h, CSF samples were centrifuged at 1800 g for 10 min at 4°C. CSF supernatant was transferred to new polypropylene tubes and stored at –20°C until further analysis (within two months). CSF Aβ₄₂ was measured with a commercially available ELISA (Innotest β-amyloid(1-42); Fujirebio, Ghent, Belgium) on a routine basis as described before [25, 26].

Sampling plasma and assaying Aβ₄₂ in plasma

Plasma samples were collected in a EDTA-blood collecting tube followed by centrifugation with a speed ranges from 1500–2500 g for 15 min at room temperature. The upper layer (plasma) was then transferred and aliquoted to 0.5 ml microcentrifuge tube and stored at –80°C or lower until further analysis. Collected plasma samples were delivered to MagQu Co., Ltd. by dry-ice package for assaying plasma Aβ₄₂ blindly.

Plasma Aβ₄₂ concentration was measured by the IMR assay [18, 27]. Amyloid β 1-42 IMR Reagent (Cat. # MF-AB2-0060; MagQu Co., Ltd., Taiwan) is made of magnetic nanoparticles (Cat. # MF-DEX-0060; MagQu Co., Ltd., Taiwan) and a specific antibody (Cat. # ab34376; Abcam, UK) against the C-terminal of Aβ₄₂. A fixed volume of IMR reagent and plasma sample (60 μl: 60μl) were mixed in sample testing tube and assayed with magnetic immunoassay analyzer (Cat. # XacPro-S; MagQu Co., Ltd., Taiwan) at room temperature. The analyzer detects the reduction percentage in the alternating current (ac) magnetic susceptibility χ_ac of IMR reagent due to the interaction of antibody-coated magnetic nanoparticles and Aβ₄₂. The reduction percentage of χ_ac signal is referred to as the IMR signal. The IMR signal was converted to the concentration of Aβ₄₂ according to the relationship between IMR signal and Aβ₄₂ concentration [21, 27]. It is not necessary to dilute EDTA plasma sample for assaying Aβ₄₂ by IMR, because the plasma Aβ₄₂ levels of both control and AD group are within the assaying range of IMR Aβ₄₂ assay (0.77–30,000 pg/ml).

Interference test of IMR plasma Aβ₄₂ assay by Aβ₄₂

Sample containing 100 pg/ml of Aβ₄₂ (Cat. # A9810; Sigma-Aldrich; USA) was reconstituted and prepared according to user’s manual. 100 pg/ml of Aβ₄₀ (Cat. # A1075; Sigma-Aldrich; USA) was used as interference material and then spiked into sample contained 100 pg/ml Aβ₄₂. The Aβ₄₂ levels were then determined by IMR Aβ₄₂ assay.

Statistical analysis

Continuous variables are presented as (mean±standard deviation). Continuous variables were compared using T-test. Spearman correlation done with GraphPad Prism, r, is performed to explore the correlation between plasma Aβ₄₂ and CSF Aβ₄₂ levels.

RESULTS

The demographic information of subjects enrolled at Sahlgrenska University (GOT) and Amsterdam (AMST) is given in Table 1. The mean values and standard deviations of CSF Aβ₄₂ level detected with conventional ELISA for each site are also shown in Table 1. The average levels of CSF Aβ₄₂ in AD groups at the two sites were 402.2±105.3 pg/ml (GOT) and 465.2±106.9 pg/ml (AMST), respectively. The CSF Aβ₄₂ levels for control groups of the two sites were 901.3±177.2 pg/ml (GOT) and 979.7±190.6 pg/ml (AMST), respectively. Combining subjects of the two sites, the CSF Aβ₄₂ level is 432.2±109.9 pg/ml for AD and 946.9±187.1 pg/ml for CONT, as given in Table 2. The combined AD group showed a significantly lower level of CSF Aβ₄₂ than the control group (p < 0.001).

Table 1

The demographic information and CSF Aβ₄₂ level of subjects in this study

Site	Group	Numbers	Age (y)	Gender (Male %)	CSF Aβ₄₂ (pg/ml)^*
Sahlgrenska University Hospital (GOT)	CONT	18	71.6±11.3	35.3%	901.3±177.2
	AD	33	80.7±9.0	53.8%	402.2±105.3
Amsterdam Dementia (AMST)	CONT	25	63.1±5.6	32.0%	979.7±190.6
	AD	30	60.4±3.2	53.5%	465.2±106.9

CONT, Control; AD, Alzheimer’s disease. ^*Mean±SD.

Table 2

Detected Aβ₄₂ levels in CSF and plasma for subjects in CONT and AD groups

Group	Numbers	CSF Aβ₄₂⁺ (pg/ml)	Plasma Aβ₄₂⁺⁺ (pg/ml)	Ratio^#
CONT	43	946.9±187.1	15.5±2.1	1.6%
AD	63	432.2±109.9	17.9±4.3	4.1%

Mean±SD; ⁺Detected using conventional ELISA; ⁺⁺Detected using IMR; ^#Aβ₄₂ level ratio of plasma to CSF.

The specificity of plasma Aβ₄₂ assay by IMR was clarified by spiking its similarity, Aβ₄₀, in sample contained Aβ₄₂ as interference material. The measured Aβ₄₂ on samples contained Aβ₄₂ only was 115.7 pg/ml. The measured Aβ₄₂ of another sample contained both Aβ₄₂ and Aβ₄₀ was quantified to be 104.6 pg/ml. The recovery rate of measured Aβ₄₂ by IMR between with and without Aβ₄₀ is 90.4% with an error range less than 10%.

Human plasma contains various and abundant endogenous biomolecules, that may interfere the measurement of IMR assay on plasma Aβ₄₂. The chemicals in medicine used to treatment inflammatory diseases, viral and bacterial infections, cardiovascular disease, and AD may also interfere. Each of these common molecules and chemicals (10,000 mg/ml of hemoglobin, 600 mg/ml of conjugated bilirubin, 30,000 mg/ml of intra lipid, 200 mg/ml of uric acid, 500 IU/ml of rheumatoid factor, 60,000 mg/ml of albumin, 500 mg/ml of acetylsalicylic acid, 300 mg/ml of ascorbic acid, 1,000 mg/ml of ampicillin sodium, 100 ng/ml of quetiapine fumarate, 90 ng/ml of galantamine hydrobromide, 100 ng/ml of rivastigmine hydrogen tartrate, 1,000 ng/ml of donepezil hydrochloride, and 150 ng/ml of memantine hydrochloride) are spiked in same plasma sample containing 115.7 pg/ml Aβ₄₂ quantified by IMR assay, separately. The measured plasma Aβ₄₂ ranges from 104.3 pg/ml to 123.8 pg/ml, and the corresponding recovery rate of measured Aβ₄₂ by IMR between with and without interfering materials is within 90.1% to 107.0% with an error range less than 10%. Taken together, this finding indicates that the Aβ_40, biomolecules, drugs and chemicals listed above do not interfere with the assay of plasma Aβ₄₂ by IMR.

In order to validate the dilution linearity of assaying Aβ₄₂ by IMR, a dilution recovery study was performed by diluting a plasma sample containing Aβ₄₂ by factors of 5, 10, 20, 50, and 100 with PBS buffer. The measured Aβ₄₂ concentration of the original sample (un-diluted) is 1059.43 pg/ml spiked with synthetic Aβ₄₂ in plasma. The dilution recoveries for samples diluted 1:5, 1:10, 1:20, and 1:50 ranged from 97.2% to 108.9% with an error range less than 10%. The dilution recovery for sample diluted 1:100 was 115.3%. So, the highest linear dilution factor is 50 times.

The plasma Aβ₄₂ levels assayed with IMR in AD at individual and combined cohorts were 17.9±4.0 pg/ml (GOT), 17.9±3.9 pg/ml (AMST), and 17.9±4.3 pg/ml (combined). In controls, the plasma Aβ₄₂ levels assayed with IMR individual and combined sites were 13.7±0.7 pg/ml (GOT), 16.8±1.8 pg/ml (AMST), and 15.5±2.1 pg/ml (combined) for CONT. The AD group showed a higher level of plasma Aβ₄₂ than the control group (p < 0.001), as shown in Table 2. The increase in plasma Aβ₄₂ level in AD patients of these European cohorts assayed with IMR is consistent with Taiwan and US studies [18 –20]. According to the results in Table 2, the ratio of Aβ₄₂ level in plasma to that in CSF was approximately 1.6% for controls and 4.1% for AD patients.

In Table 2, the opposite change in Aβ₄₂ levels in CSF and plasma between controls and AD patients is evidenced. The relationship between CSF Aβ₄₂ and plasma Aβ₄₂ of the 106 subjects is plotted in Fig. 1, showing a non-linear correlation between CSF Aβ₄₂ and plasma Aβ₄₂. Spearman correlations are used to analyse the CSF-Plasma Aβ₄₂ correlations in controls and in AD, separately. In controls, there was a weakly positive correlation between CSF Aβ₄₂ and plasma Aβ₄₂ levels (r = 0.186). However, in AD, there is a moderately negative correlation between CSF Aβ₄₂ and plasma Aβ₄₂ levels (r = –0.352). This points out that the plasma Aβ₄₂ level increases with the decreasing CSF Aβ₄₂ level in AD.

By combining the control and AD groups, all data points in Fig.1 are fitted to hyperbolic curve:

Fig.1

Relationship between plasma Aβ₄₂ and CSF Aβ₄₂ levels for control (CONT) and AD group. The solid line denotes the hyperbolic function with two asymptotic lines plotted with the dashed lines.

Plasma A β_{42} = α \frac{CSF A β_{42}}{CSF A β_{42} - φ},

(1) where α and φ are fitting parameters. By fitting the data to Eq. (1), the parameters are obtained to be 12.1 and 130.4, respectively. The fitting curve is plotted with the solid line in Fig. 1. The meanings of α and φ in Eq. (1) are the low-limited values of plasma Aβ₄₂ and CSF Aβ₄₂ levels respectively, as plotted with dashed lines in Fig. 1.

DISCUSSION

To our knowledge, this is the first report showing that plasma Aβ₄₂ levels are negatively correlated with CSF Aβ₄₂ levels in AD patients. In contrast, a previous study recently reported that both plasma and CSF Aβ₄₂ levels dropped in the dementia stage when assayed using ultrasensitive digital ELISA methodology (Simoa assay) [12]. This means that Aβ₄₂ level in plasma and in CSF assayed with Simoa showed a slightly positive correlation. The opposite finding of an inverse (negative) correlation between CSF and plasma Aβ₄₂ in the current study might be related to the different designs of technological platforms used. The Simoa method [12] is based on the sandwich assay and thus relies on the binding of two antibodies (capture and detection antibody) to measure Aβ₄₂ molecules in body fluids [12, 28], with the first antibody used to capture the N-terminal of Aβ₄₂, whereas the second antibody binds to the C-terminal domain of Aβ. Because plasma Aβ₄₂ is frequently bound to carrier proteins in blood, such as albumin or lipoproteins [29], this may induce a potential stereoscopically obstacle for two antibodies to associate with one Aβ₄₂ molecule simultaneously, with loss of some plasma Aβ₄₂ signal by using two antibodies in sandwich method. In contrast, the IMR method is a single-antibody immunoassay. The antibody specifically capturing C-terminal (a.a. 37–42) of Aβ₄₂ is anchored on the magnetic nanoparticles to detect Aβ₄₂ molecule. Based on the design of IMR assay, it ideally has a higher possibility to capture and detect Aβ₄₂ molecule when C-terminal of Aβ₄₂ is exposed in various conformations, such as isolated, complex or oligomeric forms. This may explain the different signal for IMR in comparison with the sandwich-based immunoassay when detecting Aβ₄₂. Another explanation for the differing results is that the antibody used in the IMR experiments is a polycloncal antibody that has been reported to react with several 25–85 kDa bands of unknown identity at western blot of human plasma according to the commercial vendor. It was evidenced that IMR Aβ₄₂ assay is specific for Aβ₄₂ in the presence of Aβ₄₀ in present study. Whether these are made up from oligomerized Aβ₄₂ or other anti-Aβ-reactive proteins remains to be examined.

In addition to assay methodologies, we propose the following hypothesis from the biology point of view to explain the observed negative correlation between plasma Aβ₄₂ and CSF Aβ₄₂ levels in this study. CSF Aβ₄₂ shows a significant reduction in AD patients as reported in many studies [5 –9], probably caused by aggregation and deposition of Aβ₄₂ in brain or a defect of Aβ₄₂ clearance which leads to lower amount of Aβ₄₂ molecules transport to CSF [30]. In contrast, when plasma Aβ₄₂ levels are measured by the IMR technique, there is an increase in AD [18 , 20–22], probably related to the different transportation systems to move Aβ₄₂ from the brain to the CSF and to move Aβ₄₂ from the brain to the peripheral blood. The following is our hypothesis to emphasize the impact of independent transportation system on increasing plasma Aβ₄₂ levels in AD.

It is known that some clearance systems exist for transportation of Aβ₄₂ from brain to peripheral blood in order to clean out toxic Aβ₄₂ [31]. The blood-brain barrier could play a role as a barrier to allow transportation of monomeric and soluble forms of Aβ₄₂ to the peripheral blood. The ratio of Aβ₄₂ in plasma as compared with CSF is small (<5%; Table 2), a figure similar to a previous study [32], which may indicate that only small portion of Aβ₄₂ born in brain can reach peripheral blood. But in AD, the clearance systems might keep working to transport more Aβ₄₂ to peripheral blood to avoid more Aβ₄₂ accumulating in brain. This may be one of the reasons that Aβ₄₂ level increased in peripheral blood of AD patients in the present study. An alternative explanation for the inverse correlation between plasma and CSF Aβ₄₂ levels in AD patients is the difference in composition of the matrix. The total protein concentration in blood plasma is approximately 50–70 g/l for an adult. The blood plasma is abundant in albumin (which constitute 50–60% of blood plasma proteins) that may carry substantial amounts of Aβ₄₂ [33] as compared with the amount of free Aβ₄₂. Because albumin is highly soluble in blood matrix, albumin-Aβ₄₂ complexes may be more prone to stay in a soluble form, which may prevent Aβ₄₂ from oligomerization and aggregation in blood. When Aβ₄₂ is transported from brain to peripheral blood in AD, it is thus conceivable that higher levels of soluble Aβ₄₂ in blood plasma are quantified by the IMR assay than by a sandwich immunoassay. On the other hand, the total protein level in CSF is less than 1% of that in plasma, with albumin levels around 230 mg/l as compared to 50–70 g/l in plasma [34]. In this environment with low levels of carrier proteins, aggregation-prone Aβ₄₂ molecules may relatively more easily contact with each other to form insoluble aggregates, which could reduce levels quantified by conventional sandwich immunoassays. In contrast, IMR assay shows better sensitivity and consistence when quantifying ultra-low concentration of plasma Aβ₄₂ from various and independent cohorts than conventional ELISA. In order to clarify the matrix effect in above interpretation, and to study the divergence between methodologies, a study of quantification of CSF Aβ₄₂ and plasma Aβ₄₂ by IMR assay form the same subjects is necessary.

Conclusion

We demonstrate a correlation between plasma and CSF Aβ₄₂ levels in two independent clinical cohorts. While CSF Aβ₄₂ levels were measured using sandwich ELISA methods, plasma Aβ₄₂ levels were measured with IMR, which is a technique based on a single antibody. A hyperbolic curve was found for the relationship between plasma Aβ₄₂ and CSF Aβ₄₂ in the whole set of samples. While plasma and CSF Aβ₄₂ levels were weakly positive correlated in the control group, a moderately negative correlation between plasma and CSF Aβ₄₂ levels was observed within the AD group. This negative correlation in AD presented in this study may be caused by the differences of assaying methodologies, Aβ₄₂ transportation systems or matrix effect of blood and CSF.

DISCLOSURE STATEMENT

Authors’ disclosures available online (https://www.j-alz.com/manuscript-disclosures/17-0784r1).

References

McKhann

, Knopman

, Chertkow

, Hyman

, Jack

Jr , Kawas

, Klunk

, Koroshetz

, Manly

, Mayeux

, Mohs

, Morris

, Rossor

, Scheltens

, Carrillo

, Thies

, Weintraub

, Phelps

(2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7, 263–269.

Dubois

, Feldman

, Jacova

, Hampel

, Molinuevo

, Blennow

, DeKosky

, Gauthier

, Selkoe

, Bateman

, Cappa

, Crutch

, Engelborghs

, Frisoni

, Fox

, Galasko

, Habert

, Jicha

, Nordberg

, Pasquier

, Rabinovici

, Robert

, Rowe

, Salloway

, Sarazin

, Epelbaum

, de Souza

, Vellas

, Visser

, Schneider

, Stern

, Scheltens

, Cummings

(2014) Advancing research diagnostic criteria for Alzheimer’s disease: The IWG-2 criteria. Lancet Neurol 13, 614–629.

Bateman

, Xiong

, Benzinger

TLS

, Fagan

, Goate

, Fox

, Marcus

, Cairns

, Xie

, Blazey

, Holtzman

, Santacruz

, Buckles

, Oliver

, Moulder

, Aisen

, Ghetti

, Klunk

, McDade

, Martins

, Masters

, Mayeux

, Ringman

, Rossor

, Schofield

, Sperling

, Salloway

, Morris

(2012) Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med 367, 795–804.

Buchhave

, Minthon

, Zetterberg

, Wallin

, Blennow

, Hansson

(2012) Cerebrospinal fluid levels of beta-amyloid 42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 69, 98–106.

Motter

, Vigo-Pelfrey

, Kholodenko

, Barbour

, Johnson-Wood

, Galasko

, Chang

, Miller

, Clark

, Green

, Olson

, Southwick

, Wolfert

, Munroe

, Lieberburg

, Seubert

, Schenk

(1995) Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer’s disease. Ann Neurol 38, 643–648.

Andreasen

, Davidsson

NHP

, Minthon

, Wallin

, Winblad

, Vanderstichele

, Vanmechelen

, Blennow

(1999) Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: Differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol 56, 673–680.

Wiltfang

, Esselmann

, Bibl

, Smirnov

, Paul

MOS

, Schmidt

, Klafki

, Maler

, Dyrks

, Bienert

, Beyermann

, Rüther

, Kornhuber

(2002) Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer’s disease and in patients with chronic neuroinflammation. J Neurochem 81, 481–496.

Olsson

, Vanderstichele

, Andreasen

, Meyer

, Wallin

, Holmberg

, Rosengren

, Vanmechelen

, Blennow

(2005) Simultaneous measurement of beta-amyloid(1- 42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem 51, 336–345.

Leinenbach

, Pannee

, Dülffer

, Huber

, Bittner

, Andreasson

, Gobom

, Zetterberg

, Kobold

, Portelius

, Blennow

; IFCC Scientific Division Working Group on CSF proteins (2014) Mass spectrometry-based candidate reference measurement procedure for quantification of amyloid-beta in cerebrospinal fluid. Clin Chem 60, 987–994.

10.

Blennow

, Hampel

, Weiner

, Zetterberg

(2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6, 131–144.

11.

Snyder

, Carrillo

, Grodstein

, Henriksen

, Jeromin

, Lovestone

, Mielke

, O’Bryant

, Sarasa

, Sjøgren

, Soares

, Teeling

, Trushina

, Ward

, West

, Bain

, Shineman

, Weiner

, Fillit

(2014) Developing novel blood-based biomarkers for Alzheimer’s disease. Alzheimers Dement 10 109–114 (2014).

12.

Janelidze

, Stomrud

, Palmqvist

, Zetterberg

, van Westen

, Jeromin

, Song

, Hanlon

, Hehir

CAT

, Baker

, Blennow

(2016) Plasma β-amyloid in Alzheimer’s disease and vascular disease. Sci Reports 6, 26801.

13.

Andreasson

, Blennow

, Zetterberg

(2016) Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders. Alzheimers Dement (Amst) 3, 98–102.

14.

Pannee

, Törnqvist

, Westerlund

, Ingelsson

, Lannfelt

, Brinkmalm

, Persson

, Gobom

, Svensson

, Johansson

, Zetterberg

, Blennow

, Portelius

(2014) The amyloid-β degradation pattern in plasma—A possible tool for clinical trials in Alzheimer’s disease. Neurosci Lett 573, 7–12.

15.

Ovod

, Ramsey

, Mawuenyega

, Bollinger

, Hicks

, Schneider

, Sullivan

, Paumier

, Holtzman

, Morris

, Benzinger

, Fagan

, Patterson

, Bateman

(2017) Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement 13, 841–849.

16.

Alzheimer’s Disease vs Control: Aβ42 (Plasma and Serum),http://www.alzforum.org/alzbiomarker/meta-analysis/alzheimers-disease-vs-control-av42-plasma-and-serum, Version 2.0, April 2017.

17.

O’Bryant

, Mielke

(2017) Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. Alzheimers Dement 13, 45–58.

18.

Yang

, Yang

, Chieh

, Horng

, Hong

, Yang

, Chen

, Shih

, Chen

, Chiu

(2011) Biofunctionalized magnetic nanoparticles for specifically detecting biomarkers of Alzheimer’s disease. ACS Chem Neurosci 2, 500–505.

19.

Enpuku

, Tsujita

, Nakamura

, Sasayama

, Yoshida

(2017) Biosensing utilizing magnetic markers and superconducting quantum interference devices. Supercond Sci Technol 30, 053002.

20.

Chiu

, Yang

, Chen

, Chieh

, Huang

, Yip

, Yang

, Cheng

, Chen

, Hua

, Horng

(2012) New assay for old markers-Plasma beta amyloid of mild cognitive impairment and Alzheimer’s disease. Curr Alzheimer Res 9, 1142–1148.

21.

Chiu

, Yang

, Horng

, Yang

, Chen

, Chieh

, Chen

, Ho

, Chang

, Liu

, Hong

, Yang

(2013) Combined plasma biomarkers for diagnosing mild cognition impairment and Alzheimer’s disease. ACS Chem Neurosci 18, 1530–1536.

22.

Lue

, Sabbagh

, Chiu

, Jing

, Snyder

, Schmitz

, Guerra

, Belden

, Chen

, Yang

, Walker

, Chen

, Reiman

(2017) Plasma levels of Aβ42 and tau identified probable Alzheimer’s dementia: Findings in two cohorts. Front Aging Neurosci 9, 226.

23.

Hansson

, Zetterberg

, Buchhave

, Londos

, Blennow

, Minthon

(2006) Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: A follow-up study. Lancet Neurol 5, 228–234.

24.

van der Flier

, Pijnenburg

, Prins

, Lemstra

, Bouwman

, Teunissen

, van Berckel

, Stam

, Barkhof

, Visser

, van Egmond

, Scheltens

(2014) Optimizing patient care and research: The Amsterdam Dementia Cohort. J Alzheimers Dis 41, 313–327.

25.

Mulder

, van der Flier

, Verheijen

, Mulder

, Scheltens

, Blankenstein

, Hack

, Veerhuis

(2010) BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology. J Alzheimers Dis 20, 253–260.

26.

Palmqvist

, Zetterberg

, Blennow

, Vestberg

, Andreasson

, Brooks

, Owenius

, Hägerström

, Wollmer

, Minthon

, Hansson

(2014) Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-Amyloid 42: A cross-validation study against amyloid positron emission tomography. JAMA Neurol 71, 1282–1289.

27.

Yang

, Chieh

, Yang

, Liao

, Chen

, Horng

, Yang

, Hong

, Chiu

, Chen

, Huang

, Wu

(2013) Clinic applications in assaying ultra-low-concentration bio-markers using HTS SQUID-based AC magnetosusptometer. IEEE Trans Appl Supercond 3, 23–26.

28.

Song

, Lachno

, Hanlon

, Shepro

, Jeromin

, Gemani

, Talbot

, Racke

, Dage

, Dean

(2016) A digital enzyme-linked immunosorbent assay for ultrasensitive measurement of amyloid-β 1–42 peptide in human plasma with utility for studies of Alzheimer’s disease therapeutics. Alzheimers Res Ther 8, 58.

29.

Biere

, Ostaszewski

, Stimson

, Hyman

, Maggio

, Selkoe

(1996) Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma. J Biol Chem 271, 32916–32922.

30.

Blennow

, Mattsson

, Scholl

, Hansson

, Zetterberg

(2015) Amyloid biomarkers in Alzheimer’s disease. Trends Pharmacol Sci 36, 297–309.

31.

Tarasoff-Conway

, Carare

, Osorio

, Glodzik

, Butler

, Fieremans

, Axel

, Rusinek

, Nicholson

, Zlokovic

, Frangione

, Blennow

, Ménard

, Zetterberg

, Wisniewski

, de Leon

(2015) Clearance systems in the brain—implications for Alzheimer disease. Nat Rev Neurol 11, 457–470.

32.

Tarasoff-Conway

, Carare

, Osorio

, Glodzik

, Butler

, Fieremans

, Axel

, Rusinek

, Nicholson

, Zlokovic

, Frangione

, Blennow

, Ménard

, Zetterberg

, Wisniewski

, de Leon

(2014) Amyloid-β efflux from the CNS into the plasma. Ann Neurol 76, 837–844.

33.

Burtis

, Ashwood

(1999) Tietz Textbook of Clinical Chemistry. 3rd ed.Philadelphia, PA.

34.

Blennow

, Fredman

, Wallin

, Gottfries

, Karlsson

, Långström

, Skoog

, Svennerholm

, Wikkelsö

(1993) Protein analyses in cerebrospinal fluid: II. Reference values derived from healthy individuals 18-88 years of age. Eur Neurol 33, 129–133.

Plasma Amyloid-β (Aβ 42 ) Correlates with Cerebrospinal Fluid Aβ 42 in Alzheimer’s Disease

Abstract

Keywords

INTRODUCTION

MATERIALS AND METHODS

Study populations

CSF biochemical analysis

Sampling plasma and assaying Aβ42 in plasma

Interference test of IMR plasma Aβ42 assay by Aβ42

Statistical analysis

RESULTS

DISCUSSION

Conclusion

DISCLOSURE STATEMENT

References

Sampling plasma and assaying Aβ₄₂ in plasma

Interference test of IMR plasma Aβ₄₂ assay by Aβ₄₂